GB201603291D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB201603291D0
GB201603291D0 GBGB1603291.4A GB201603291A GB201603291D0 GB 201603291 D0 GB201603291 D0 GB 201603291D0 GB 201603291 A GB201603291 A GB 201603291A GB 201603291 D0 GB201603291 D0 GB 201603291D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1603291.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Binding Site Group Ltd
Original Assignee
Binding Site Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201603291(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Binding Site Group Ltd filed Critical Binding Site Group Ltd
Priority to GBGB1603291.4A priority Critical patent/GB201603291D0/en
Publication of GB201603291D0 publication Critical patent/GB201603291D0/en
Priority to US16/078,986 priority patent/US12461108B2/en
Priority to JP2018544901A priority patent/JP7246927B2/ja
Priority to CN202211574983.0A priority patent/CN116148479A/zh
Priority to ES17708323T priority patent/ES2942315T3/es
Priority to KR1020187027703A priority patent/KR102851057B1/ko
Priority to ES17708320T priority patent/ES2936783T3/es
Priority to EP17708323.5A priority patent/EP3420362B1/en
Priority to AU2017222399A priority patent/AU2017222399B2/en
Priority to BR112018067435A priority patent/BR112018067435A2/pt
Priority to PCT/GB2017/050489 priority patent/WO2017144900A1/en
Priority to EP22190012.9A priority patent/EP4123308A1/en
Priority to US16/079,165 priority patent/US20190048064A1/en
Priority to AU2017222402A priority patent/AU2017222402B2/en
Priority to CA3015296A priority patent/CA3015296A1/en
Priority to EP17708320.1A priority patent/EP3420361B1/en
Priority to DK17708320.1T priority patent/DK3420361T3/da
Priority to PCT/GB2017/050492 priority patent/WO2017144903A1/en
Priority to CN201780013491.5A priority patent/CN108885218A/zh
Priority to JP2022017497A priority patent/JP7541045B2/ja
Priority to JP2022198753A priority patent/JP7541070B2/ja
Priority to US18/454,967 priority patent/US20230391851A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34Purifying; Cleaning
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00Chemical aspects of mass spectrometric analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
GBGB1603291.4A 2016-02-25 2016-02-25 Antibodies Ceased GB201603291D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB1603291.4A GB201603291D0 (en) 2016-02-25 2016-02-25 Antibodies
PCT/GB2017/050492 WO2017144903A1 (en) 2016-02-25 2017-02-24 Antibodies
CN201780013491.5A CN108885218A (zh) 2016-02-25 2017-02-24 质谱法试剂盒
BR112018067435A BR112018067435A2 (pt) 2016-02-25 2017-02-24 kit de espectrometria de massa
US16/079,165 US20190048064A1 (en) 2016-02-25 2017-02-24 Antibodies
CN202211574983.0A CN116148479A (zh) 2016-02-25 2017-02-24 质谱法试剂盒
ES17708323T ES2942315T3 (es) 2016-02-25 2017-02-24 Anticuerpos
KR1020187027703A KR102851057B1 (ko) 2016-02-25 2017-02-24 질량 분석 키트
ES17708320T ES2936783T3 (es) 2016-02-25 2017-02-24 Kit de espectrometría de masas
EP17708323.5A EP3420362B1 (en) 2016-02-25 2017-02-24 Antibodies
AU2017222399A AU2017222399B2 (en) 2016-02-25 2017-02-24 Mass spectrometry kit
US16/078,986 US12461108B2 (en) 2016-02-25 2017-02-24 Mass spectrometry kit including a cross-linked antibody or fragment thereof
PCT/GB2017/050489 WO2017144900A1 (en) 2016-02-25 2017-02-24 Mass spectrometry kit
EP22190012.9A EP4123308A1 (en) 2016-02-25 2017-02-24 Mass spectrometry kit
JP2018544901A JP7246927B2 (ja) 2016-02-25 2017-02-24 質量分析キット
AU2017222402A AU2017222402B2 (en) 2016-02-25 2017-02-24 Antibodies
CA3015296A CA3015296A1 (en) 2016-02-25 2017-02-24 Mass spectrometry kit
EP17708320.1A EP3420361B1 (en) 2016-02-25 2017-02-24 Mass spectrometry kit
DK17708320.1T DK3420361T3 (da) 2016-02-25 2017-02-24 Massespektrometrikit
JP2022017497A JP7541045B2 (ja) 2016-02-25 2022-02-07 質量分析キット
JP2022198753A JP7541070B2 (ja) 2016-02-25 2022-12-13 質量分析キット
US18/454,967 US20230391851A1 (en) 2016-02-25 2023-08-24 Antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1603291.4A GB201603291D0 (en) 2016-02-25 2016-02-25 Antibodies

Publications (1)

Publication Number Publication Date
GB201603291D0 true GB201603291D0 (en) 2016-04-13

Family

ID=55806928

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1603291.4A Ceased GB201603291D0 (en) 2016-02-25 2016-02-25 Antibodies

Country Status (12)

Country Link
US (1) US12461108B2 (enExample)
EP (2) EP4123308A1 (enExample)
JP (3) JP7246927B2 (enExample)
KR (1) KR102851057B1 (enExample)
CN (2) CN116148479A (enExample)
AU (1) AU2017222399B2 (enExample)
BR (1) BR112018067435A2 (enExample)
CA (1) CA3015296A1 (enExample)
DK (1) DK3420361T3 (enExample)
ES (1) ES2936783T3 (enExample)
GB (1) GB201603291D0 (enExample)
WO (1) WO2017144900A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708262D0 (en) 2017-05-23 2017-07-05 Binding Site Group Ltd Assay for plasma cell associated disease
SG11202108033TA (en) * 2019-01-31 2021-08-30 Regeneron Pharma Native microfluidic ce-ms analysis of antibody charge heterogeneity
CN110009008B (zh) * 2019-03-18 2020-11-06 四川大学 基于提取的免疫固定电泳图特征对其进行自动分类的方法
GB201906599D0 (en) 2019-05-10 2019-06-26 Binding Site Group Ltd Mass spectrometry calibrator
CN113811772B (zh) * 2019-05-10 2024-12-06 结合点集团有限公司 质谱分析校准物
GB201915946D0 (en) 2019-11-01 2019-12-18 Binding Site Group Ltd Quantitation of immunoglobulins i n mass spectrometry
GB202007047D0 (en) * 2020-05-13 2020-06-24 Binding Site Group Ltd Mass spectrometry controls
GB202008887D0 (en) * 2020-06-11 2020-07-29 Binding Site Group Ltd A method of identifying or characterising an immune response in a subject
GB202016822D0 (en) 2020-10-23 2020-12-09 Binding Site Group Ltd Quantitation of immunoglobulins in mass spectrometry
CN113720900A (zh) * 2021-09-14 2021-11-30 首都医科大学附属北京朝阳医院 一种基于madli-tof ms技术检测血清中m蛋白的方法
CN114324557B (zh) * 2021-12-03 2024-05-10 融智生物科技(青岛)有限公司 一种基于MALDI-TOF MS的ζ-珠蛋白的检测方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
WO1991006570A1 (en) * 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ATE294959T1 (de) * 1994-05-13 2005-05-15 Miltenyi Biotec Gmbh An protein gebundene sterile und pyrogenfreie säulen zum binden und entfernen von substanzen aus blut
JP2826965B2 (ja) * 1995-01-12 1998-11-18 オリエンタル酵母工業株式会社 免疫吸着体とその製造法
DE69634092T2 (de) 1995-11-03 2005-12-08 The Binding Site Ltd. Herstellung von antikörpern
US6207370B1 (en) * 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
KR20070007253A (ko) * 2003-10-08 2007-01-15 이바이오사이언스 천연 면역글로불린 결합 물질 및 이의 제조 방법 및 사용방법
WO2006099481A2 (en) 2005-03-14 2006-09-21 Medimmune, Inc. Macromolecules comprising a thioether cross-link
DE602006020850D1 (de) 2005-04-12 2011-05-05 Akira Matsumori Biomarker zur diagnose einer herzerkrankung sowie verwendung davon
US7893616B2 (en) * 2006-02-27 2011-02-22 Ohio State University Process to determine enzyme activity
WO2008079914A1 (en) 2006-12-21 2008-07-03 Novartis Ag Antibody quantitation
RU2012118620A (ru) 2009-10-09 2013-11-20 Симфоген А/С Множественное количественное определение в смеси индивидуальных рекомбинантных белков посредством сигнатурных пептидов и масс-спектрометрии
GB201001946D0 (en) 2010-02-05 2010-03-24 Binding Site Group The Ltd Cancer prognostic assay
GB2478520A (en) 2010-03-02 2011-09-14 Binding Site Group Ltd Kidney prognostic assay
GB201117172D0 (en) 2011-10-05 2011-11-16 Binding Site Group The Ltd Diabetes
GB201121265D0 (en) 2011-12-12 2012-01-18 Binding Site Group The Ltd Assay
US20150031861A1 (en) 2012-03-09 2015-01-29 Ucl Business Plc Chemical Modification of Antibodies
WO2014121031A1 (en) 2013-01-31 2014-08-07 Excelimmune, Inc. Characterization of antibody mixtures by mass spectrometry
WO2015131169A2 (en) * 2014-02-28 2015-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Personalized myeloma detection
US10267806B2 (en) 2014-04-04 2019-04-23 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
US10690676B2 (en) * 2014-07-29 2020-06-23 Mayo Roundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by LC-MS/MS
AU2015334455B2 (en) * 2014-10-21 2020-05-21 Gennova Biopharmaceuticals Limited A novel purification process for isolation and commercial production of recombinant TNK-tPA (Tenecteplase)
US11209439B2 (en) 2015-09-24 2021-12-28 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry

Also Published As

Publication number Publication date
AU2017222399A1 (en) 2018-08-30
JP7541045B2 (ja) 2024-08-27
CN108885218A (zh) 2018-11-23
KR20180132651A (ko) 2018-12-12
EP3420361B1 (en) 2023-01-04
US20190094239A1 (en) 2019-03-28
JP7246927B2 (ja) 2023-03-28
CN116148479A (zh) 2023-05-23
US12461108B2 (en) 2025-11-04
AU2017222399B2 (en) 2024-03-14
BR112018067435A2 (pt) 2019-01-02
JP2019509483A (ja) 2019-04-04
EP3420361A1 (en) 2019-01-02
EP4123308A1 (en) 2023-01-25
JP2023033281A (ja) 2023-03-10
DK3420361T3 (da) 2023-01-23
WO2017144900A1 (en) 2017-08-31
JP7541070B2 (ja) 2024-08-27
KR102851057B1 (ko) 2025-08-28
ES2936783T3 (es) 2023-03-22
JP2022069446A (ja) 2022-05-11
CA3015296A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
ZA201900373B (en) Anti-tim-3 antibodies
IL259048A (en) Antibodies against ror-1
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
SG10201913864RA (en) Anti-LAG-3 Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
IL253633B (en) Anti-transthyretin antibodies
GB201521393D0 (en) Antibodies
GB201521391D0 (en) Antibodies
GB201610044D0 (en) Antibodies
PL3250593T3 (pl) Przeciwciała przeciwko transtyretynie
SG10202010735PA (en) Tau-binding antibodies
GB201521382D0 (en) Antibodies
IL255323A0 (en) Anti-fcrn antibodies
GB201616699D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201603291D0 (en) Antibodies
PT3484921T (pt) Anticorpos anti-il-22r
IL260083A (en) Antibody against myl9
GB201509907D0 (en) Antibodies
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
IL284022B1 (en) Anti-transthyretin antibodies
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)